Every Form 4 that Conexeu Sciences Inc. (CNXU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNXU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNXU filings page.
Conexeu Sciences Inc. (CNXU) insider Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, exercised warrants to acquire 217,608 shares of common stock at $2.30 per share on September 4, 2026. The amendment clarifies that the same 217,608 warrants were disposed of upon exercise, correcting a prior coding error. After the transaction, entities managed by OnePointTwo Capital Management LLC hold 2,951,848 shares of common stock and 407,392 warrants indirectly attributable to Purcell, who may be deemed a beneficial owner but disclaims beneficial ownership beyond any pecuniary interest. No Rule 10b5-1 trading plan is reported.
Conexeu Sciences Inc. (CNXU) reported that director and ten percent owner Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, exercised warrants to acquire 217,608 shares of common stock on September 4, 2026 at an exercise price of $2.30 per share. Following the exercise, entities managed by OnePointTwo Capital Management LLC held 2,951,848 shares of common stock and 407,392 warrants, all reported as indirect holdings over which Purcell has voting and investment power but for which he disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported.
Conexeu Sciences Inc. director and 10% owner Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, reported significant indirect insider activity in common stock and warrants on 2026-06-18. The LLC bought 202,500 shares of common stock at $0.80 per share, bringing its indirect common stock holdings to 2,734,240 shares. It also exercised warrants for 202,500 underlying common shares at an exercise price of $0.80 and separately bought 202,500 additional warrants at $0.001 per warrant, each exercisable for common stock at $2.30 per share, leaving 625,000 warrants indirectly held.
Conexeu Sciences Inc. ten percent owner Wright Michael G., through N3GU Investments LLC, exercised derivative securities to acquire 250,000 shares of Common Stock at $0.001 per share. Following this transaction, N3GU Investments LLC indirectly holds 2,148,048 Common shares. The Performance Warrants were originally granted for services, totaling 900,000, of which 650,000 have vested; the remaining 250,000 will vest and be exercisable when the company submits a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. insider entity N3GU Investments LLC, over which reporting person Michael G. Wright has sole voting and dispositive power, exercised 400,000 Performance Warrants to acquire 400,000 shares of Common Stock at $0.001 per share, all held indirectly.
Following the transactions, N3GU Investments LLC indirectly held 1,898,048 shares of Common Stock and 500,000 remaining Performance Warrants. The original grant covered 900,000 Performance Warrants, with future vesting tied to an >$80,000,000 market capitalization milestone and submission of a 510(k) application to the U.S. Food and Drug Administration.